ScottDRowleyMD

Professor of Medicine - Georgetown University School of Medicine; Director, Bone Marrow and Stem Cell Transplant Program, MedStar Georgetown University Hospital; Associate Professor of Medicine, UMDNJ - New Jersey Medical School Newark

Join to view full profile

Dr. Rowley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rowley's full profile

Already have an account?

Office
92 2nd St
Hackensack, NJ 07601
Phone+1 551-996-8297

Fax+1 551-996-0575

Summary

Dr. Scott Rowley is an oncologist in Hackensack, NJ and is affiliated with multiple hospitals in the area, including Hackensack Meridian Health Hackensack University Medical Center and MedStar Georgetown University Hospital. He received his medical degree from University of Massachusetts Medical School and has been in practice 39 years. He specializes in hematologic oncology and is experienced in hematologic oncology, transplant medicine, and cellular immunotherapy.

Scott Rowley, M.D., takes a personalized approach to treatment based the patient

Dr. Scott Rowley, director of the Stem Cell Transplantation and Cellular Therapy Program at John Theurer Cancer Center, is part of a comprehensive team of...

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1983 - 1984
Brown UniversityResidency, Internal Medicine, 1978 - 1981
University of Massachusetts Medical SchoolClass of 1978

Certifications & Licensure

FL State Medical License 2024 - 2026
MD State Medical License 1981 - 2025
NJ State Medical License 2000 - 2025
NY State Medical License 2012 - 2025
DC State Medical License 2012 - 2024
VA State Medical License 2023 - 2024
WA State Medical License 1991 - 2002
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2016
Inside Jersey Magazine Top Doctors Castle Connolly, 2010-2016
Top Doctors: New York Metro Area Castle Connolly, 2009-2016
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
New York Magazine: Top Doctors Castle Connolly, 2009-2013
America's Top Doctors for Cancer Castle Connolly, 2009-2013
Inside Jersey Top Doctors for Cancer Castle Connolly, 2012
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia Start of enrollment: 1999 Feb 01
Completed
Phase 1, Phase 2
Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) Start of enrollment: 2003 Nov 01
Completed
Phase 3
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) Start of enrollment: 2004 Aug 01
Terminated
Phase 2, Phase 3
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) Start of enrollment: 2006 Jan 01
Completed
Phase 1, Phase 2
Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy Start of enrollment: 2007 Oct 01
Completed
Phase 2, Phase 3
Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma Start of enrollment: 2007 Jan 01
Completed
Phase 1, Phase 2
Stem Cell Related Donor Safety Study Start of enrollment: 2010 Jan 01
Completed
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT Start of enrollment: 2010 May 11
Completed
Phase 1, Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Start of enrollment: 2010 Jun 09
Completed
Phase 2
Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen Start of enrollment: 2011 Nov 01
Completed
Phase 2
Treating Cancer-Related Fatigue Through Systematic Light Exposure Start of enrollment: 2012 Jan 01
Completed
Not Applicable
Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML Start of enrollment: 2014 Feb 06
Completed
Phase 2
Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation Start of enrollment: 2015 Jul 07
Terminated
Not Applicable
Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes Start of enrollment: 2015 May 01
Active, not recruiting
Not Applicable
Observational Trial to Evaluate Hematopoietic Stem Cell Transplantation CMV Reactivation Start of enrollment: 2015 Jun 01
Completed
Join now to see all

Publications & Presentations

PubMed

Correction: Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study.
Joseph P McGuirk, Leland Metheny 3rd, Luis Pineiro, Mark Litzow, Scott D Rowley
Bone Marrow Transplantation. 2024-12-03
Randomized Phase III SIERRA Trial ofI-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R Litzow
Journal of Clinical Oncology. 2024-09-19
Greater Social Isolation and Social Constraints Prior to Hematopoietic Stem Cell Transplant Are Associated with Greater Anxiety and Depressive Symptoms.
Layan Shahrour, Joseph Martinez, Anthony Chicaiza, Rahma Omar, Katrin Bovbjerg
International Journal of Behavioral Medicine. 2024-06-01

Journal Articles

Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms and Less Complete Recovery at 1-Year Compared to Unrelated Donors
Parameswaran N Hari, David A Jacobsohn, Joseph P McGuirk, Mary M Horowitz, Walter Longo, Thomas Spitzer, Daniel J Weisdorf, Shahram Mori, David C Delgado, Marcie L Ric..., Haematologica

Abstracts/Posters

Evomela¬ Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation
Scott D. Rowley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Elotuzumab As Post-Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Myeloma
Scott D. Rowley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Pilot Study of Telmisartan (Micardis) for Prevention of Acute Graft Vs. Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: Interim Analysis
Scott D. Rowley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Sustained Hematopoietic Recovery after Salvage Autologous Stem Cell Transplants after Long Term Storage of Cryopreserved Hematopoietic Progenitor Stem Cells (HPSC)
Scott D. Rowley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients
Scott D. Rowley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treat...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplan...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

The Foundation for the Accreditation of Cellular Therapy (FACT) Recognizes MedStar Georgetown University Hospital for Excellence in Adult Allogeneic and Autologous Hematopoietic Progenitor Cellular Therapy, Immune Effector Cellular Therapy, and Marrow and Blood Donation ProcessMay 19th, 2022
Recent FDA Designation Puts Promising Engineered Cellular Therapy That Reduces Complications of Lymphoma Treatment on Accelerated Path to Market ApprovalFebruary 16th, 2021
John Theurer Cancer Center (JTCC) Researchers to Present 52 Abstracts Across Hematological Malignancies at the 2020 American Society of Hematology (ASH) Annual Meeting and ExpositionDecember 4th, 2020
Join now to see all